Developing BET-ter treatments for cutaneous T-cell lymphoma

Affiliations

Comment

Henry K Wong. Oncotarget. 2019.

. 2019 Feb 12;10(13):1267-1268.

doi: 10.18632/oncotarget.26662.

¹ Henry K. Wong: Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

No abstract available

Keywords: T cell; bromodomain; lymphoma; mycosis fungoides; sezary syndrome.

Comment on

BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition.
Kim SR, Lewis JM, Cyrenne BM, Monico PF, Mirza FN, Carlson KR, Foss FM, Girardi M. Kim SR, et al. Oncotarget. 2018 Jun 26;9(49):29193-29207. doi: 10.18632/oncotarget.25670. eCollection 2018 Jun 26. Oncotarget. 2018. PMID: 30018745 Free PMC article.

1. Wong HK, et al. Br J Haematol. 2011;155:150–66. doi: 10.1111/j.1365-2141.2011.08852.x. - DOI - PMC - PubMed
1. Agar NS, et al. J Clin Oncol. 2010;28:4730–9. doi: 10.1200/JCO.2009.27.7665. - DOI - PubMed
1. Jawed SI, et al. J Am Acad Dermatol. 2014;70:223 e1–17. doi: 10.1016/j.jaad.2013.08.033. - DOI - PubMed
1. Whittaker S, et al. Blood. 2016;127:3142–53. doi: 10.1182/blood-2015-12-611830. - DOI - PubMed
1. Choi J, et al. Nat Genet. 2015;47:1011–9. doi: 10.1038/ng.3356. - DOI - PMC - PubMed